stockportfolio.pro
Sana Biotechnology, Inc. (SANA)
Healthcare · Biotechnology · NasdaqGS
Sana Biotechnology, Inc. revenue & earnings — last 7 fiscal years
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | — | — | — | — | — | — | — |
| Net income | $-130.78M | $-285.31M | $-355.93M | $-269.48M | $-283.25M | $-266.76M | $-244.17M |
| Net margin | — | — | — | — | — | — | — |
Source: Sana Biotechnology, Inc. SEC filings (10-K).
Explore 7 years of Sana Biotechnology, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track SANA in your portfolio →
Sana Biotechnology, Inc. financial history by metric
About Sana Biotechnology, Inc.
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company's product pipeline includes UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical trial to treat type 1 diabetes; SC451, a HIP-modified, stem cell derived pancreatic islet cell therapy, which is in preclinical trial for the treatment of type 1 diabetes; SG293 and SG299, a CD8-targeted fusosome for the treatment of B cell hematologic malignancies and B cell mediated autoimmune diseases. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company has a strategic collaboration with Mayo Clinic for the development of SC451, a hypoimmune-modified pancreatic islet cell therapy for type 1 diabetes. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.
Sana Biotechnology, Inc. — frequently asked questions
What is Sana Biotechnology, Inc.'s revenue?
Sana Biotechnology, Inc. (SANA) reported revenue of $0 for fiscal year 2025, according to its SEC filings.
Is Sana Biotechnology, Inc. profitable?
No — SANA reported a net loss of $-244.17M in fiscal 2025.
What is SANA's P/E ratio?
Sana Biotechnology, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Sana Biotechnology, Inc. have?
As of fiscal year 2025, SANA carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Sana Biotechnology, Inc.'s market cap?
Sana Biotechnology, Inc. (SANA) has a market capitalization of about $794.52M, based on the latest data in our nightly-refreshed cache.
When does Sana Biotechnology, Inc.'s fiscal year end?
SANA's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Sana Biotechnology, Inc.'s official SEC filings (10-K and 10-Q), covering 7 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.